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Abstract
Objectives Children with juvenile idiopathic arthritis (JIA) may be predisposed to serious pneumonia due to modern disease-
modifying anti-rheumatic treatment. In this nationwide retrospective study with clinical data, we describe the pneumonia
episodes among children with JIA.
Methods Patients under 18 years of age with JIA and pneumonia during 1998–2014 were identified in the National Hospital
Discharge Register in Finland. Each individual patient record was reviewed, and detailed data on patients with JIA and pneu-
monia were retrieved, recorded, and analyzed. If the patient was hospitalized or received intravenous antibiotics, the pneumonia
was considered serious.
Results There were 157 episodes of pneumonia among 140 children with JIA; 111 episodes (71%) were serious (80% in 1998–
2006 and 66% in 2007–2014). The mean age of the patients was 9 years. Forty-eight percent had active JIA and 46% had
comorbidities. Disease-modifying anti-rheumatic drugs (DMARD) were used at the time of 135 episodes (86%): methotrexate
(MTX) by 62% and biologic DMARDs (bDMARD) by 30%. There was no significant difference in the use of bDMARDs,MTX
and glucocorticoids between the patient groups with serious and non-serious pneumonia episodes. During six of the episodes,
intensive care was needed. Two patients (1.3%) died, the remaining ones recovered fully.
Conclusions Although the incidence of pneumonia and the use of immunosuppressive treatment among children with JIA
increased from 1998 to 2014, the proportion of serious pneumonias in these patients decreased. There was no significant
difference in the use of anti-rheumatic medication between patients with serious and non-serious pneumonia.
Key Points
• The incidence of serious pneumonias decreased from 1998 to 2014 among children with juvenile idiopathic arthritis (JIA).
• There was no significant difference in the use of the disease-modifying anti-rheumatic medication between JIA patients with serious and non-serious
pneumonias.
• Active JIA, comorbidities, and combination medication were associated with nearly half of the pneumonias.
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Introduction
The outcome of juvenile idiopathic arthritis (JIA) has im-
proved significantly as medications have developed, much
due to the advent of biologic disease-modifying anti-rheumat-
ic drugs (bDMARD) [1]. However, the adverse effects of im-
munosuppressive medication, including infections, are not
fully known. The risk of infections in children with JIA is
related to the JIA itself, to concurrent illnesses and to the
immunosuppressive treatment [2]. JIA patients without med-
ication have a 2-fold incidence of bacterial infections requir-
ing hospitalization when compared with a control population
of similar age [3]. The use of glucocorticoids (GC) increases
the risk of serious infections, while the effects of methotrexate
(MTX) and the most common group of bDMARDs used to
treat pediatric patients, tumor necrosis factor alpha inhibitors
(TNFIs), have yielded contradictory results on the occurrence
of infections [4]. Modern, effective immunosuppressive med-
ication may increase the risk of serious infections, but it im-
proves, at the same time, the control of JIA and reduces the
overall risk of infections [5]. Pneumonia is one of the most
common serious infections in children with JIA [5–7].
Recently, we reported that the rate of pneumonia increased
in Finnish children with JIA as well as in the general popula-
tion of corresponding age during the years 1999–2014. At the
same time, the use of MTX and bDMARD increased signifi-
cantly among JIA patients, while the use of GC remained
unchanged [8]. For this paper, we have analyzed the patient
data from 1998 to 2014 to describe in further detail the sever-
ity of pneumonia in this patient group and its relationship, if
any, to immunosuppressive medication.
Materials and methods
Data source
The data for this national retrospective study was retrieved
from the National Hospital Discharge Register (Care
Register for Health Care; HILMO) maintained by the
National Institute for Health and Welfare. This register has
been described in our previous study [8]. Because hospital
outpatient data was entered into the HILMO register starting
from 1998, our previous register study on the incidence of
pneumonia covered the years beginning with 1999 until
2014 to get reliable register information. For the present study,
all data available on patients with JIA and radiographically
verified pneumonia were retrieved from patient records cov-
ering the time from 1998 to 2014.
The coordinating ethics committee of the Helsinki and
Uusimaa Hospital District approved the study protocol (228/
13/03/00/10) and the use of the Care Register for Health Care
(HILMO) data.
Study population
We used the HILMO register to retrieve nationwide data on
children younger than 16 years with JIA (diagnose codes
M08.0–M08.9) during 1998–2014. They were followed until
the day theywere 18 years or to the end of 2014.We linked the
identity codes of these patients to the diagnosis of bacterial or
undefined pneumonia (J13–J18.9). Pneumonias before the di-
agnosis of JIAwere excluded.
Patient records
The data on JIA and pneumonia was confirmed by reviewing
the individual patient records obtained from the treating hos-
pitals. The study group comprised JIA patients with radio-
graphically verified pneumonia (pulmonary infiltrate)
assessed by a radiologist and a pediatrician. We collected the
information on JIA and pneumonia from the patient records as
described in our previous study [8].
Pneumonia was defined as serious, if the patient was hos-
pitalized or treated with intravenous antibiotics [9, 10]. The
pneumonia was considered hospital-acquired if it developed
48 h or later after hospital admission for other reasons [11].
The activity of JIA was assessed by scrutiny of the patient
record entries of the previous hospital visit or at the time of
the pneumonia. JIAwas considered inactive if the patient had
no active arthritis, no general symptoms (fever, rash, serositis)
and no active uveitis, and if the erythrocyte sedimentation rate
(ESR) and/or the C-reactive protein (CRP) were within the
reference range before the pneumonia diagnosis [12].
Otherwise, the JIA was considered to be active. No activity
scores were available. The use of GC was divided into two
groups: more than 10 mg or less than 10 mg of prednisolone
equivalent per day. Antibiotic therapies started within 2 weeks
before pneumonia episodes were included in the analysis.
Readmission was defined as a new hospital admission if it
occurred within 30 days after hospital discharge for pneumo-
nia [13].
Statistics
Patient and pneumonia episode characteristics were described
by frequencies, percentages, and means (with the respective
standard deviations) or medians (with other quartiles).
Differences in patient characteristics and anti-rheumatic med-
ication at the time of the pneumonia episodes were analyzed
with Fisher’s exact test or with the Mann-Whitney test. The
risk factors for serious pneumonia were assessed by logistic
regression with serious pneumonia as the dependent variable.
The independent variables were active JIA, JIA duration
(more/less than 2 years), previous recurrent infections, asth-
ma, age (higher/lower than 5 years), combination medication,
MTX, bDMARD, GC, previous antibiotic therapy, and
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follow-up period (1998–2006 and 2007–2014). Instability in
the regression models due to over-fitting and probable
multicollinearity may affect substantially the estimate values
and the generalizability of the results. As one solution to this
problem, we additionally used logistic regression with a
backward selection procedure, where the probability of
the Wald statistic was used with the removal p value of
0.10. Also, the best model based on the Akaike informa-
tion criterion (AIC) was defined. Analyses were per-
formed with the SPSS statistics software, version 25.0
and with the R-version 3.3.0 (R: A language and environ-
ment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria).
Results
Characteristics of JIA patients with pneumonia
There were altogether 59,048 JIA patient years during the
follow-up. In 1998–2006, the number of children with JIA
per year varied between 2292 and 3575 and in 2007–2014
between 3633 and 4511. We identified 157 pneumonia epi-
sodes in 140 children with JIA. Of the pneumonia episodes,
111 were serious (70.7%) and all except one were community-
acquired. Nineteen patients (13.6%) had inactive JIA and were
not on DMARD treatment. Fourteen JIA patients (10%) had
an episode of pneumonia within the first 3 months of diagno-
sis. Almost half (45.7%) of the JIA patients with pneumonia
had some concurrent illness; the most common were asthma
(17.9%) and Down syndrome (7.1%) (Table 1). Previous re-
current infections had affected 22 children (15.7%).
Altogether 15 JIA patients (10.7%) had recurrent pneumo-
nias. They had 32 pneumonia episodes of which 18 (56.3%)
were serious. Comorbidities affected 12 of these patients
(80%). Two patients had three pneumonias: One of them
had aggressive systemic JIA (sJIA) treated with GC (> 10
mg/day), and one had seronegative polyarthritis and Down
syndrome associated with neutropenia and recurrent
infections.
JIA medication at the time of pneumonia
At the time of the pneumonia episodes, 86% of the patients
used DMARDs and 48.4% combination medication (Table 2).
Altogether 68.1% of bDMARD users took concomitantly
MTX and 38.3% took GC; 8.5% took a daily dose of ≥
10 mg prednisolone equivalent of GC. The use of MTX in-
creased from 51 to 68% and of bDMARDs from 15 to 40%
from 1998–2006 to 2007–2014. TNFIs (83%) were the most
common bDMARDs (etanercept 42.6%). Anti-rheumatic
medications with tocilizumab, anakinra, and GC (≥ 10 mg/
day) were associated exclusively with serious pneumonia
episodes (Table 2). Patients stood on DMARDs during 28
out of the 32 (87.5%) recurrent pneumonia episodes: Eight
(25%) took GC and 13 (40.6%) took bDMARDs. Six patients
were treated in the intensive care unit; two of them used
bDMARDs and four GCs. Immunosuppressive therapy for
JIA (except GC) was always discontinued when pneumonia
was treated.
Diagnostic testing
Altogether 80 blood cultures (BC) were obtained from the
patients with serious pneumonia (72.1%); of these, five were
bacteria-culture positive (6.3%), and one was a contamination
(1.3%). Streptococcus pneumoniae was detected in three
cases: One patient was in remission without medication; one
took a combination of prednisolone (1.25 mg/day),
leflunomide, and hydroxychloroquine; and one had active
sJIA treated with a combination of prednisolone (10 mg/
day), MTX, and bDMARD. The CRP, ESR, and leucocyte
values were within the reference range of one JIA patient on
tocilizumab, prednisolone (26 mg/day), and leflunomide de-
spite Staphylococcus aureus sepsis and pneumonia.
A microbiological etiology was verified in 21 episodes
(13.4%): Mycoplasma pneumoniae in six, Influenza A in
three, Rhinovirus in two, and Chlamydia pneumoniae in two
episodes. Respiratory syncytial and Parainfluenza viruses
were detected in one episode each (Table 3). There were no
multiresistant microbes. One patient with active JIA treated
with prednisolone (10 mg/day),MTX, and certolizumab (third
bDMARD) had an episode of complicated pneumonia with
prolonged intermittent fever and developed subsequently ce-
rebral Mycobacterium tuberculosis abscesses.
Outcome of pneumonia
Of the 157 episodes of pneumonia, 105 (66.9%) were treated
with parenteral antibiotics, more than half with cephalosporins
(57.1%). The mean duration of antibiotic treatment was 10
days. Twelve pneumonia episodes (7.6%) required two or
more consecutive courses of antibiotics.
The median duration of hospital stay was 3 days (range 1–
114 days). Six episodes were treated in the intensive care unit.
Nine pneumonia episodes (8.1%) were followed by readmis-
sion: Seven were due to pneumonia, one to diarrhea, and one
to active JIA. Of the 32 recurrent pneumonia episodes, two led
to readmission and three required intensive care. Minimal or
moderate pleural effusion was present in ten pneumonia epi-
sodes (6.4%). None of the patients needed mechanical venti-
lation, pleural drainage, or other invasive procedures. Four
bronchoscopies were performed because of prolonged cough
or hemoptysis: Infection was diagnosed in three and primary
ciliary dyskinesia (Kartagener syndrome) in one.
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Two patients died (1.3%). In 1998, a 10-year-old girl, who
had aggressive seronegative polyarthritis for 9 years, was
treated with GC (15 mg/day), azathioprine, and MTX. Since
the disease did not remit, she was further treated with an
autologous stem cell transplantation after which she required
prolonged intensive care period. She developed neutropenia,
pneumonia, and Candida albicans sepsis. She died of acute
respiratory distress and heart failure. In 2000, a 7-year-old girl
Table 1 Characteristics of 140 individual patients with juvenile idiopathic arthritis and pneumonia at the time of the first pneumonia
All patients (n = 140) Serious pneumonia* (n = 101) Non-serious pneumonia* (n = 39)
Age, mean (SD), years 9.4 (4.8) 9.1 (4.9) 10.2 (4.5)
Female, n (%) 83 (59.3) 59 (58.4) 24 (61.5)
JIA duration, median (Q1–Q3), years 2.6 (1.0–6.2) 2.6 (1.0–6.9) 2.6 (1.0–5.9)
< 2 years, n (%) 56 (40.0) 39 (38.6) 17 (43.6)
Systemic arthritis, n (%) 10 (7.1) 9 (8.9) 1 (2.6)
Oligoarthritis, n (%) 63 (45.0) 41 (40.6) 22 (56.4)
Polyarthritis, n (%) 64 (45.7) 48 (47.5) 16 (41.0)
Others 3 (2.1) 3 (3.0) 0
Uveitis, n (%) 34 (24.3) 25 (24.8) 9 (23.1)
Active JIA, n (%) 67 (47.9) 51 (50.5) 16 (41.0)
Comorbidities, n (%) 64 (45.7) 46 (45.5) 18 (46.2)
Asthma 25 (17.9) 14 (13.9) 11 (28.2)
Down syndrome 10 (7.1) 7 (6.9) 3 (7.7)
Iatrogenic adrenal insufficiency 7 (5.0) 6 (5.9) 1 (2.6)
Diabetes mellitus 3 (2.1) 2 (2.0) 1 (2.6)
IBD 2 (1.4) 2 (2.0) 0
Others 17 (12.1) 15 (14.9) 2 (5.1)
JIA juvenile idiopathic arthritis, Q1-Q3 lower-upper quartile, IBD inflammatory bowel disease
*There were no statistically significant differences between serious and non-serious pneumonia groups (Fisher’s exact test or the Mann-Whitney test)
Table 2 Anti-rheumatic medication at the time of 157 pneumonia episodes among patients with juvenile idiopathic arthritis
Medication All
(n = 157)
Serious pneumonia episodes
(n = 111)
Non-serious pneumonia episodes
(n = 46)
MTX, n (%) 97 (61.8) 66 (59.5) 31 (67.4)
Duration of MTX use, median (Q1–Q3) (years, n = 66 + 31) 1.6 (0.6–3.4) 1.7 (0.6–3.3) 1.6 (0.5–4.2)
bDMARD, n (%) 47 (29.9) 30 (27.0) 17 (37.0)
TNFI 39 (24.8) 23 (20.7) 16 (34.8)
Tocilizumab 5 (3.2) 5 (4.5) 0
Anakinra 2 (1.3) 2 (1.8) 0
Abatacept 1 (0.6) 0 1 (2.2)
Duration of bDMARD use, median (Q1–Q3) (years, n = 30 + 17) 1.3 (0.7–3.3) 1.1 (0.5–2.1)* 2.9 (0.9–4.6)*
≥ 1 prior biologic agent, n (%) 17 (10.8) 9 (8.1) 8 (17.4)
GC any dose, n (%) 26 (16.6) 22 (19.8) 4 (8.7)
≥ 10 mg prednisolone equivalent dose of GC, n (%) 8 (5.1) 8 (7.2) 0
Duration of GC use, median (Q1–Q3) (years, n = 22 + 4) 2.4 (0.7–5.1) 2.0 (0.6–2.0) 3.6 (1.7–4.8)
Combination medication, n (%) 76 (48.4) 58 (52.3) 18 (39.1)
Without medication, n (%) 22 (14.0) 17 (15.3) 5 (10.9)
MTXmethotrexate, Q1-Q3 lower-upper quartile, bDMARD biologic disease-modifying anti-rheumatic drug, TNFI tumor necrosis factor alpha inhibitor,
GC glucocorticoid
*The duration of bDMARD use was significantly shorter (p = 0.046) in the serious pneumonia group compared to the non-serious group (the Mann-
Whitney test). There were no other statistically significant differences between serious and non-serious pneumonia groups (the Mann-Whitney test or
Fisher’s exact test). Only those who used anti-rheumatic medication were included in the statistical analysis
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with active sJIA for nearly 5 years was diagnosed with lobar
pneumonia and pleuritis. Before the pneumonia, she had been
treated with etanercept for 1 year combined with GC and
hydroxychloroquine. She died of respiratory failure due to
pneumonia.
Comparison of serious and non-serious pneumonia
episodes
During the first half of the follow-up (1998–2006), 49 of 61
(80%) and during the latter half (2007–2014) 52 of 79 JIA
patients (66%) had an episode of serious pneumonia (p =
0.104). There was a trend of children under 5 years being
hospitalized more often than older children (p = 0.069)
(Table 4). There were no significant differences in the other
patient characteristics between the serious and non-serious
pneumonia groups (Table 1). The children with non-serious
pneumonia, in comparison with those with serious pneumo-
nia, had a trend of having previously more often recurrent
infections (OR 0.34, 95% CI 0.11–1.04, p = 0.058) and asth-
ma (OR 0.39, 95% CI 0.14–1.11, p = 0.078) (Table 4). The
regression model in Table 4 may have been over-fitted. The
Table 4 Comparison of serious and non-serious pneumonias at the time of the first pneumonia in 140 patients with juvenile idiopathic arthritis, logistic
regression analysis
Variable, n (%) Serious pneumonia (n = 101) Non-serious pneumonia (n = 39) OR (95% CI)* p value
Active JIA 51 (50.5) 16 (41.0) 1.44 (0.59–3.61) 0.432
JIA duration < 2 years 39 (38.6) 17 (43.6) 0.67 (0.23–1.93) 0.458
History of infections 13 (12.9) 9 (23.1) 0.34 (0.11–1.04) 0.058
Asthma 14 (13.9) 11 (28.2) 0.39 (0.14–1.11) 0.078
Age < 5 years 27 (26.7) 6 (15.4) 2.93 (0.92–9.35) 0.069
Combination medication 49 (48.5) 15 (38.5) 3.00 (0.83–10.9) 0.095
MTX 59 (58.4) 26 (66.7) 0.53 (0.24–1.36) 0.183
bDMARD 27 (26.7) 13 (33.3) 0.34 (0.09–1.22) 0.098
Glucocorticoid 19 (18.8) 4 (10.3) 2.69 (0.61–12.0) 0.193
Previous antibiotic therapy 18 (17.8) 9 (23.1) 0.66 (0.24–1.82) 0.424
Follow-up period
1998–2006 49 (80.3) 12 (19.7) 1 } 0.104
2007–2014 52 (65.8) 27 (34.2) 0.46 (0.18-1.17)
Variables remaining in the final model using Akaike information criterion are italicized. Significant variables after backward elimination are in bold
JIA juvenile idiopathic arthritis, MTX methotrexate, bDMARD biologic disease-modifying anti-rheumatic drug, CI confidence interval
*Odds ratios (OR) were assessed by logistic regression with serious pneumonia as the dependent variable
Table 3 Symptoms and laboratory findings at the time of 157 pneumonia episodes among patients with juvenile idiopathic arthritis
All
(n = 157)
Serious pneumonia
(n = 111)
Non-serious pneumonia
(n = 46)
p value
Symptom, n (%)
Fever (> 38°) 141 (89.8) 104 (94.5)a 37 (80.4) 0.014
Cough 140 (89.2) 96 (86.5) 44 (95.7) 0.155
Dyspnea 24 (15.3) 20 (18.0) 4 (8.7) 0.222
Chest pain 16 (10.2) 15 (13.5) 1 (2.2) 0.040
Vomiting 21 (13.4) 19 (17.1) 2 (4.3) 0.038
Duration of symptoms (days) before diagnosis, median (Q1–Q3) 6 (3–12.3) 5 (3–7) 7 (4–14) 0.003
Duration of fever (days) before diagnosis median (Q1–Q3) (n = 110 + 46) 2 (1–4) 2 (1–4) 2.5 (1–4) 0.952
CRP, median (Q1–Q3), mg/mL 77 (28–150) 91 (41–179) 46 (11.3–106.5) < 0.001
Leucocytes, median (Q1–Q3), E9/L 11.6 (7.0–17.4) 13.1 (7.4–18.8) 7.4 (6.1–12.2) < 0.001
Microbiological diagnosis, n (%) 21 (13.4) 17 (15.3) 4 (8.7) 0.315
The data was analyzed by Fisher’s exact test or by the Mann-Whitney test
Q1-Q3 lower-upper quartile, CRP C-reactive protein
a 94.5% (104/110), information on one patient’s fever symptom was not available
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best result when using the AIC criterion for model selection
contained the following variables: follow-up period (p =
0.030), previous recurrent infections (p = 0.032), asthma (p
= 0.051), GC (p = 0.069), and age (p = 0.126).When using the
backward elimination procedure to the full model, only asth-
ma (p = 0.039) and follow-up period (p = 0.047) remained in
the final model.
The most distinct difference in the use of anti-rheumatic med-
ication before pneumonia episodes was a significantly shorter
period of bDMARDuse among childrenwith serious pneumonia
than non-serious pneumonia (p = 0.046) (Table 2). JIA patients
with serious pneumonia sought hospital treatment significantly
earlier than patients with non-serious pneumonia (p = 0.003)
(Table 3). The leucocyte (p < 0.001) and CRP (p < 0.001) values
were significantly higher among the children with serious pneu-
monia than non-serious pneumonia (Table 3). The use of antibi-
otic therapy before the pneumonia episodes was similar in the
two groups (Table 4), and there was no difference with regard to
the use of consecutive antibiotic courses.
Discussion
In this Finnish national register-based, real-world study, there
were 157 episodes of mainly community-acquired pneumonia
among 140 JIA patients; 71% of these episodes were serious.
In our previous study, the overall incidence of pneumonia
increased through 1999–2014, and during the latter half of
the follow-up period (2007–2014), it was significantly higher
among patients with JIA than in the general population of
similar age [8]. Since there were signs of collinearity with
some of the target covariates, the model presented in Table 4
was probably over-fitted. The model was reduced with two
different methods, and the results corroborate the finding that
the rate of pneumonia, defined as serious, in fact decreased
from 1998–2006 to 2007–2014 among JIA patients. Maybe
treating patterns for pneumonia have shifted towards favoring
outpatient care which would decrease the recorded rate of
serious pneumonias, since serious pneumonia was defined as
pneumonia treated in a hospital or with intravenous antibi-
otics. On the other hand, maybe shifts in the treatment and
follow-up practices of JIA patients have changed in a direction
favoring a better contact between patients and the health care
system. If so, the health care system would catch upper respi-
ratory infections and incipient pneumonias at an earlier stage,
and earlier intervention would reduce the risk of the patient
developing serious pneumonia. It is also worth noting that a
decrease in pneumonia rates has been reported after introduc-
tion of pneumococcal vaccination into the Finnish national
vaccination program in 2010 [14].
Active JIA, expressed in terms of the clinical Juvenile
Arthritis Disease Activity Score (cJADAS10), is an independent
risk factor for serious infections [9]. Within 2 years after
JIA has been diagnosed and treated, on average, 78% of patients
experience inactivation of the disease; for patients with
rheumatoid-factor positive polyarthritis, the figure is 48% [15].
In this study, nearly half of the JIA patients had active disease
(Table 1) and 10% of the pneumonia episodes occurred within 3
months after JIA had been diagnosed. A study from Germany
concluded that patients on immunosuppressive therapy have a
high risk for pneumonia and that patients with ≥ 2 at-risk condi-
tions (e.g., rheumatoid arthritis, asthma, Down syndrome, diabe-
tes) have a similar or higher risk of pneumonia compared with
patients on immunosuppressive therapy [16]. Our results corrob-
orate these findings: 46% of our patients had some concurrent
illness ormorbidity, and 16%had had recurrent infections. Of the
recurrent pneumonias, 80% occurred in patients with some co-
morbidity and 88% in patients on DMARD therapy.
Children hospitalized for community-acquired pneumonia
(CAP) have frequent asthma [17]. Hospitalization for CAP is
greatest in children under 5 years of age and one third of them
have asthma [18, 19]. In our study, there was a trend for more
frequent hospitalization of children under 5 years than older
children. Altogether 18% of JIA patients with pneumonia had
asthma and of them 56% were hospitalized (Table 1). There
was a trend for asthma being more common in the non-serious
pneumonia group (OR 0.39, 95% CI 0.14–1.11, p = 0.078)
(Table 4), which could be due to more intensive treatment of
asthma and pneumonia.
Altogether 7% of JIA patients with pneumonia had Down
syndrome. The prevalence of Down syndrome in Finland is
0.27% [20], and the prevalence of JIA among children with
Down syndrome is 6-fold (0.87%) compared with JIA in the
general population [21]. Thus, we corroborated previous find-
ings [16] that JIA patients with Down syndrome have a higher
than average risk of pneumonia.
In our study, there was a trend for a history of infec-
tions being associated more often with non-serious than
serious pneumonia (OR 0.34, 95% CI 0.11–1.04, p =
0.058) in JIA patients. Antibiotic therapy may be started
in these children earlier and more efficiently than before.
The rate of outpatient antibiotic prescriptions for children
on MTX and/or TNFI is about two times higher than the
rate among children not on this medication [22]. We
found no significant difference in the previous use of an-
timicrobials between the serious and non-serious pneumo-
nia groups (Table 4).
Effective treatment of JIA has increased during the last 20
years, but still most pediatric JIA patients have active disease
and need long-term treatment [23–25]. In Finland, 72% of
recently diagnosed JIA patients used MTX about a decade
ago [26], and 66% of adolescents and young adults with JIA
took MTX, 29% bDMARDs, and 9% GCs [23]. In our study,
combination medication was used by nearly half of the pa-
tients with JIA and pneumonia and, in the latter half of the
follow-up, 40% of JIA patients were on bDMARDs. Serious
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infections account for one third of all serious adverse events
attributed to bDMARDs [27]. In a recent study, three out of
307 children with JIA on bDMARD therapy (1%) had a seri-
ous infection during 1 year of follow-up [28].
When immunosuppressive drugs are combined, the total
immunosuppressive effect is at least as powerful as with the
most immunosuppressive agent used alone [5]. A study on US
Medicaid data reported that there was no significant risk for
infections requiring hospital treatment among patients on
TNFI monotherapy or on TNFI in combination with MTX
[7]. Nor did we find any significant difference in the occur-
rence of serious and non-serious pneumonia episodes in rela-
tion to the use of MTX and bDMARDs. In adults with rheu-
matoid arthritis, a dose-related association between GC use
and the risk of hospitalization for pneumonia has been report-
ed [29]. In the present study, daily doses of GC ≥ 10 mg were
in use only at the time of the serious pneumonia episodes
(Table 2), which would support this observation.
Serious infections in adults with rheumatic diseases usually
occur during the first 6months after start of TNFI therapy [30]. A
recent study pointed out that when TNFIs are introduced into the
treatment of JIA in children, the risk of serious infections rises
2.7-fold compared with the introduction of DMARDs; here, the
mean follow-up time was 307 days [4]. In our study, the mean
duration of bDMARD use was significantly shorter (p = 0.046)
among children with serious pneumonia episodes than non-
serious pneumonia episodes (Table 2).
The microbiological diagnosis of pneumonia is challeng-
ing. The current management guidelines for CAP recommend
BCs if the patient is hospitalized and the pneumonia is mod-
erate or severe [31]. In a multicenter study, BCs were taken of
56% of the children hospitalized for CAP, and bacteremia was
present in 7% [32]. In our study, BCs were taken of 72% of the
patients with five positive findings in children with serious
pneumonia (6%). CRP was obtained of nearly all JIA patients
with pneumonia (Table 3). CRP and the leucocyte values do
not necessarily predict the degree of severity of the lung in-
fection in patients taking bDMARDs [10]. In agreement with
this, there was one patient on tocilizumab who had
Staphylococcus aureus sepsis, but whose CRP and leucocyte
values were within the reference range.
In our study, there were no suppurative complications and
none of the patients needed pleural drainage. The JIA patients
recovered largelywell on antibiotics, although prolonged courses
of antibiotic therapy were needed in 12 episodes (7.6%) and
hospital readmission in nine (8%). Up to 8% of children with
pneumonia are readmitted for hospital treatment, and the rate of
readmission increases if the patient has chronic comorbidities
[13]. Abinun et al. [33] described four patients with refractory
JIA on combined DMARD therapy who developed unexpected-
ly a severe infection and died. In our series, two patients died in
the beginning of the follow-up; both had disabling JIA and
required long-term multiple and combined DMARD therapy,
including a dose of GC ≥ 10 mg/day.
To our knowledge, this is the first detailed, nationwide,
real-world study on JIA and pneumonia. The strength of our
study is that it is based on comprehensive national register
data which covers the entire hospital network in Finland.
Pediatric rheumatologists attend to children with JIA in the
hospitals, and the appropriate ICD diagnoses are available
from the HILMO register. In addition to register data, we
collected detailed data from patient records and analyzed only
radiographically verified pneumonias.
On the other hand, register datamay include errors of diagnosis,
although we checked painstakingly all registry data from individ-
ual patient records. The clinical data on patient records was also
incomplete, e.g., data on growth, vaccinations, and clinical signs of
pneumonia were only partially available. Therefore, it was not
possible to define the severity of pneumonia based on clinical
signs, and general guidelines (e.g., American or British Thoracic
Society guidelines) could not be used. Because an etiological di-
agnosis of pneumonia is often difficult to obtain and because this
study was retrospective, we focused on bacterial pneumonia ICD
codes. Unfortunately, it was not feasible to compare JIA patients
with and without pneumonia because selecting appropriate con-
trols would have been an unsurmountable task. Milder cases of
pneumonia are treated by open-care physicians, and thus, this data
is not available. Overall, the rather low number of pneumonia
episodes did not allow for all statistical calculations that would
have been of interest, like analyzing the subtypes of JIA.
Conclusion
Despite the increasing incidence of pneumonia and use of im-
munosuppressive treatment among children with JIA, the pro-
portion of serious pneumonias in these patients has decreased
over time. Active JIA, comorbidities and combination medica-
tion were associated with nearly half of the pneumonias. There
was no significant difference in the use of bDMARD, MTX, or
GC between patients with serious and non-serious pneumonia,
but this observation needs to be corroborated by further studies.
Clinicians should always keep in mind the possibility of serious
infectious complications in these immunocompromised patients.
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